卡立泊来德
卡立泊来德 性质
| 熔点 | 90-94° (dec) |
|---|---|
| 密度 | 1.34 |
| 储存条件 | 2-8°C |
| 溶解度 | 不溶于水； DMSO 中≥12.05 mg/mL；温和加热和超声波下，乙醇中≥2.675 mg/mL |
| 形态 | 粉末 |
| 颜色 | 白色至米色 |
| InChI | InChI=1S/C12H17N3O3S/c1-7(2)9-5-4-8(11(16)15-12(13)14)6-10(9)19(3,17)18/h4-7H,1-3H3,(H4,13,14,15,16) |
| InChIKey | IWXNYAIICFKCTM-UHFFFAOYSA-N |
| SMILES | C1(S(=O)(=O)C)=CC(=CC=C1C(C)C)C(=O)/N=C(\N)/N |
卡立泊来德 用途与合成方法
| Target | Value |
|
NHE1
(CHO-K1 cells) | 30 nM |
Cariporide significantly suppresses markers of cell death, such as TUNEL positivity and caspase-3 cleavage, at 8 or 16 hours. Cariporide remarkably suppresses cytosolic Na + and Ca 2+ accumulation. Cariporide prevents mitochondrial membrane potential loss induced by H 2+ O 2+ . Cariporide (HOE-642) ameliorates myocardial ischemia/reperfusion injury, by the well-established reduction of cytosolic Ca 2+ in cardiac myocytes through inhibition of Na + /H + exchange. Cariporide (HOE-642), has inhibitory effects on the degranulation of human platelets, the formation of platelet–leukocyte-aggregates, and the activation of the GPIIb/IIIa receptor (PAC-1).
Intravenous administration of cariporide significantly decreases brain Na + uptake and reduces cerebral edema, brain swelling, and infarct volume.
卡立泊来德 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-09-15 | HY-19693R | 卡立泊来德 | 159138-80-4 | 5 mg | 1375 |
| 2026-09-15 | HY-19693 | 卡立泊来德 | 159138-80-4 | 1 mg | 250 |
